Because our science is life changing
We continuously build on our legacy as the leading radiopharmaceutical-focused company, enabling healthcare professionals to Find, Fight and Follow® disease through the development of next-generation radiodiagnostics, targeted radiotherapeutics and radiotheranostic pairs.
Finding and fighting disease at the source
Radiopharmaceuticals are an essential component of nuclear medicine, harnessing the power of radioactive isotopes to advance precision diagnostic imaging and targeted therapeutics.
Radiodiagnostics
Radiotracers are administered to localize in targeted tissue and, when paired with PET imaging, help physicians diagnose, stage and monitor disease.1
Radiotherapeutics
These therapies use targeting molecules that bind to cancer cells and deliver high doses of radiation while limiting damage to surrounding healthy tissue.2
Radiotheranostics
This approach pairs diagnostic and therapeutic techniques to improve diagnostic accuracy, treatment efficacy and patient response monitoring.
Our focus areas
At Lantheus, we are investigating several early- and late-stage innovative radiodiagnostic and radiotherapeutic candidates across core disease areas of oncology, neurology and cardiology.
Oncology
1 in 5 people globally will develop cancer in their lifetime, creating a significant need for earlier diagnosis and targeted treatment.3 We’re focused on complementary radiodiagnostic and radiotherapeutic pairs, called radiotheranostics.
Neurology
With someone in the world developing dementia every 3 seconds,4 our focus is on supporting earlier detection, staging and monitoring of Alzheimer’s and other forms of dementia.
Cardiology
As the leading cause of death worldwide, cardiovascular disease remains an area of high unmet need.5 With our history in cardiovascular precision diagnostics, we’re innovating solutions to enable informed decisions for patients with heart disease.
The future of radiopharmaceuticals
The radiopharmaceutical market is predicted to experience rapid growth over the next decade.5 At Lantheus, we are building on our foundation as a leader in this space to power the future of radiopharmaceuticals and improve patient outcomes.
REFERENCES
1. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. JACC. Published December 2, 2025. Accessed February 5, 2026. https://doi.org/10.1016/j.jacc.2025.08.015 2. EANM Position Paper. European Association of Nuclear Medicine. Published May 2024. Accessed May 21, 2025. https://eanm.org/wp-content/uploads/2024/05/EANM-overarching-narrative_0707.pdf 3. Global Cancer Burden Growing, Amidst Mounting Need for Services. World Health Organization. Published February 4, 2024. Accessed September 10, 2025. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services 4. Dementia Statistics. Alzheimer’s Disease International. Accessed September 10, 2025. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/ 5. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. JACC. Published December 2, 2025. Accessed February 5, 2026. https://doi.org/10.1016/j.jacc.2025.08.015 6. MEDraysintell 2024 Nuclear Medicine Report. MEDraysintell. Published October 9, 2024. Accessed May 21, 2025.
